Review: The utility of magnetic resonance imaging for assessing structural damage in randomized controlled trials in rheumatoid arthritis

Arthritis and Rheumatism

Volumn 65, Issue 10, 2013, Pages 2513-2523

  Strand, Vibeke ^a  

^a Biopharmaceutical Consultant   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; BARICITINIB; CYCLOSPORIN; DENOSUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FOSTAMATINIB; GADOLINIUM; GOLIMUMAB; METHOTREXATE; PLACEBO; RITUXIMAB; TOCILIZUMAB;

BONE EROSION; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; CONSTRUCT VALIDITY; CONTENT VALIDITY; CRITERION RELATED VALIDITY; DOPPLER ECHOGRAPHY; ECHOGRAPHY; FACE VALIDITY; GOLD STANDARD; HUMAN; INFLAMMATION; INTERMETHOD COMPARISON; JOINT INJURY; META ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEITIS; OUTCOME ASSESSMENT; PREDICTIVE VALIDITY; PRIORITY JOURNAL; RADIODIAGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELIABILITY; REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOID ARTHRITIS MAGNETIC RESONANCE IMAGING SCORING; SCORING SYSTEM; SYNOVITIS; SYSTEMATIC REVIEW; TENDINITIS; TREATMENT RESPONSE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; HUMANS; JOINTS; MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84885152521     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.38083     Document Type: Review

References (71)

1. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69: 631-7.
2. American College of Rheumatology Rheumatoid Arthritis Clinical Trial Investigators Ad Hoc Task Force. American College of Rheumatology Clinical Trial Priorities and Design Conference, July 22-23, 2010. Arthritis Rheum 2011; 63: 2151-6.
3. McQueen F, Lassere M, Edmonds J, Conaghan P, Peterfy C, Bird P, et al. OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies: summary of OMERACT 6 MR imaging module. J Rheumatol 2003; 30: 1387-92.
4. Ostergaard M, Peterfy C, Conaghan P, McQueen F, Bird P, Ejbjerg B, et al. OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies: core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. J Rheumatol 2003; 30: 1385-6.
5. Conaghan P, Bird P, Ejbjerg B, O'Connor P, Peterfy C, McQueen F, et al. The EULAR-OMERACT rheumatoid arthritis MRI reference image atlas: the metacarpophalangeal joints. Ann Rheum Dis 2005; 64 Suppl 1: i11-21.
6. Ejbjerg B, McQueen F, Lassere M, Haavardsholm E, Conaghan P, O'Connor P, et al. The EULAR-OMERACT rheumatoid arthritis MRI reference image atlas: the wrist joint. Ann Rheum Dis 2005; 64 Suppl 1: i23-47.
7. Ostergaard M, Edmonds J, McQueen F, Peterfy C, Lassere M, Ejbjerg B, et al. An introduction to the EULAR-OMERACT rheumatoid arthritis MRI reference image atlas. Ann Rheum Dis 2005; 64 Suppl 1: i3-7.
8. Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, et al, on behalf of the Denosumab Rheumatoid Arthritis Study Group. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008; 58: 1299-309.
9. Conaghan PG, Durez P, Alten RE, Burmester GR, Tak PP, Klareskog L, et al. Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial. Ann Rheum Dis 2013; 72: 1287-94.
10. Conaghan PG, Peterfy CG, DiCarlo J, Olech E, Alberts AR, Alper JA, et al. Early reductions in tissue inflammation with tocilizumab as either monotherapy or in combination with methotrexate: 12-week unblinded results from a magnetic resonance imaging substudy of a randomized controlled trial [abstract]. Arthritis Rheum 2011; 63 Suppl: S165-6.
11. Genovese MC, Kavanaugh A, Weinblatt ME, Peterfy C, DiCarlo J, White ML, et al. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum 2011; 63: 337-45.
12. Peterfy CG, Haraoui B, Kavanaugh A, Smolen JS, Santra S, Kupper H, et al. Baseline levels of the inflammatory biomarker C-reactive protein are significantly correlated with magnetic resonance imaging measures of synovitis at baseline and after 26 weeks of treatment in patients with early rheumatoid arthritis [abstract]. Arthritis Rheum 2011; 63 Suppl: S629-30.
13. Peterfy C, Emery P, Tak PP, Ostergaard M, DiCarlo J, Otsa K, et al. Rituximab (RTX) plus methotrexate (MTX) prevents bone erosion and joint-space narrowing (JSN) and reduces synovitis, osteitis as shown on MRI: results from a randomised, placebo-controlled trial in patients (PTS) with rheumatoid arthritis (RA-SCORE). Ann Rheum Dis 2011; 70 Suppl 3: iii152.
14. Peterfy CG, Olech E, DiCarlo JC, Merrill JT, Countryman PJ, Gaylis NB,. Monitoring cartilage loss in the hands and wrists in rheumatoid arthritis with magnetic resonance imaging in a multi-center clinical trial: IMPRESS (NCT00425932). Arthritis Res Ther 2013; 15: R44.
15. Higgins JP, Green S, editors. Cochrane highly sensitive search strategy for identifying randomized trials in MEDLINE: sensitivity-maximizing version (2008 revision). In: Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. URL: www.cochrane-handbook.org.
16. Boers M, Brooks P, Strand CV, Tugwell P,. The OMERACT filter for outcome measures in rheumatology. J Rheumatol 1998; 25: 198-9.
17. US Food and Drug Administration. Guidance for industry: preparation of IDEs and INDs for products intended to repair or replace knee cartilage. December 2011. URL: http://www.fda.gov/downloads/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/ UCM288011.pdf.
18. Peterfy CG, Emery P, Genovese MC, Keystone E, Taylor P, Berclaz PY, et al. Magnetic resonance imaging substudy in a phase 2b dose-ranging study of baricitinib, an oral janus kinase 1/janus kinase 2 inhibitor, in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 2012; 64 Suppl: S1050-1.
19. Dohn UM, Ejbjerg BJ, Hasselquist M, Narvestad E, Court-Payen M, Szkudlarek M, et al. Rheumatoid arthritis bone erosion volumes on CT and MRI: reliability and correlations with erosion scores on CT, MRI and radiography. Ann Rheum Dis 2007; 66: 1388-92.
20. Ostendorf B, Peters R, Dann P, Becker A, Scherer A, Wedekind F, et al. Magnetic resonance imaging and miniarthroscopy of metacarpophalangeal joints: sensitive detection of morphologic changes in rheumatoid arthritis. Arthritis Rheum 2001; 44: 2492-502.
21. Perry D, Stewart N, Benton N, Robinson E, Yeoman S, Crabbe J, et al. Detection of erosions in the rheumatoid hand; a comparative study of multidetector computerized tomography versus magnetic resonance scanning. J Rheumatol 2005; 32: 256-67.
22. Dohn UM, Ejbjerg BJ, Court-Payen M, Hasselquist M, Narvestad E, Szkudlarek M, et al. Are bone erosions detected by magnetic resonance imaging and ultrasonography true erosions? A comparison with computed tomography in rheumatoid arthritis metacarpophalangeal joints. Arthritis Res Ther 2006; 8: R110.
23. Gaffney K, Cookson J, Blades S, Coumbe A, Blake D,. Quantitative assessment of the rheumatoid synovial microvascular bed by gadolinium-DTPA enhanced magnetic resonance imaging. Ann Rheum Dis 1998; 57: 152-7.
24. Gaffney K, Cookson J, Blake D, Coumbe A, Blades S,. Quantification of rheumatoid synovitis by magnetic resonance imaging. Arthritis Rheum 1995; 38: 1610-7.
25. Ostergaard M,. Different approaches to synovial membrane volume determination by magnetic resonance imaging: manual versus automated segmentation. Br J Rheumatol 1997; 36: 1166-77.
26. Ostergaard M, Stoltenberg M, Lovgreen-Nielsen P, Volck B, Sonne-Holm S, Lorenzen I,. Quantification of synovitis by MRI: correlation between dynamic and static gadolinium-enhanced magnetic resonance imaging and microscopic and macroscopic signs of synovial inflammation. Magn Reson Imaging 1998; 16: 743-54.
27. Tamai K, Yamato M, Yamaguchi T, Ohno W,. Dynamic magnetic resonance imaging for the evaluation of synovitis in patients with rheumatoid arthritis. Arthritis Rheum 1994; 37: 1151-7.
28. Conaghan PG, O'Connor P, McGonagle D, Astin P, Wakefield RJ, Gibbon WW, et al. Elucidation of the relationship between synovitis and bone damage: a randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis. Arthritis Rheum 2003; 48: 64-71.
29. Jimenez-Boj E, Nobauer-Huhmann I, Hanslik-Schnabel B, Dorotka R, Wanivenhaus AH, Kainberger F, et al. Bone erosions and bone marrow edema as defined by magnetic resonance imaging reflect true bone marrow inflammation in rheumatoid arthritis. Arthritis Rheum 2007; 56: 1118-24.
30. McQueen FM, Gao A, Ostergaard M, King A, Shalley G, Robinson E, et al. High-grade MRI bone oedema is common within the surgical field in rheumatoid arthritis patients undergoing joint replacement and is associated with osteitis in subchondral bone. Ann Rheum Dis 2007; 66: 1581-7.
31. Foley-Nolan D, Stack JP, Ryan M, Redmond U, Barry C, Ennis J, et al. Magnetic resonance imaging in the assessment of rheumatoid arthritis-a comparison with plain film radiographs. Br J Rheumatol 1991; 30: 101-6.
32. Jorgensen C, Cyteval C, Anaya JM, Baron MP, Lamarque JL, Sany J,. Sensitivity of magnetic resonance imaging of the wrist in very early rheumatoid arthritis. Clin Exp Rheumatol 1993; 11: 163-8.
33. Klarlund M, Ostergaard M, Jensen KE, Madsen JL, Skjodt H, Lorenzen I, and the TIRA Group. Magnetic resonance imaging, radiography, and scintigraphy of the finger joints: one year follow up of patients with early arthritis. Ann Rheum Dis 2000; 59: 521-8.
34. McQueen FM, Stewart N, Crabbe J, Robinson E, Yeoman S, Tan PL, et al. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset. Ann Rheum Dis 1998; 57: 350-6.
35. Hoving JL, Buchbinder R, Hall S, Lawler G, Coombs P, McNealy S, et al. A comparison of magnetic resonance imaging, sonography, and radiography of the hand in patients with early rheumatoid arthritis. J Rheumatol 2004; 31: 663-75.
36. Rahmani M, Chegini H, Najafizadeh SR, Azimi M, Habibollahi P, Shakiba M,. Detection of bone erosion in early rheumatoid arthritis: ultrasonography and conventional radiography versus non-contrast magnetic resonance imaging. Clin Rheumatol 2010; 29: 883-91.
37. Szkudlarek M, Klarlund M, Narvestad E, Court-Payen M, Strandberg C, Jensen KE, et al. Ultrasonography of the metacarpophalangeal and proximal interphalangeal joints in rheumatoid arthritis: a comparison with magnetic resonance imaging, conventional radiography and clinical examination. Arthritis Res Ther 2006; 8: R52.
38. Emery P, van der Heijde D, Ostergaard M, Conaghan PG, Genovese MC, Keystone EC, et al. Exploratory analyses of the association of MRI with clinical, laboratory and radiographic findings in patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70: 2126-30.
39. Brown AK, Quinn MA, Karim Z, Conaghan PG, Peterfy CG, Hensor E, et al. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug- induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum 2006; 54: 3761-73.
40. Brown AK, Conaghan PG, Karim Z, Quinn MA, Ikeda K, Peterfy CG, et al. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum 2008; 58: 2958-67.
41. Gandjbakhch F, Conaghan PG, Ejbjerg B, Haavardsholm EA, Foltz V, Brown AK, et al. Synovitis and osteitis are very frequent in rheumatoid arthritis clinical remission: results from an MRI study of 294 patients in clinical remission or low disease activity state. J Rheumatol 2011; 38: 2039-44.
42. Gandjbakhch F, Foltz V, Mallet A, Bourgeois P, Fautrel B,. Bone marrow oedema predicts structural progression in a 1-year follow-up of 85 patients with RA in remission or with low disease activity with low-field MRI. Ann Rheum Dis 2011; 70: 2159-62.
43. Haavardsholm EA, Gandjbakhch F, Conaghan P, Ejbjerg BJ, Foltz V, Brown A, et al. Towards imaging remission: determining a MRI inflammatory activity acceptable state in rheumatoid arthritis. Ann Rheum Dis 2012; 71 Suppl 3: iii149.
44. McQueen F, Beckley V, Crabbe J, Robinson E, Yeoman S, Stewart N,. Magnetic resonance imaging evidence of tendinopathy in early rheumatoid arthritis predicts tendon rupture at six years. Arthritis Rheum 2005; 52: 744-51.
45. McQueen FM, Stewart N, Crabbe J, Robinson E, Yeoman S, Tan PL, et al. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals progression of erosions despite clinical improvement. Ann Rheum Dis 1999; 58: 156-63.
46. Ostergaard M, Hansen M, Stoltenberg M, Gideon P, Klarlund M, Jensen KE, et al. Magnetic resonance imaging-determined synovial membrane volume as a marker of disease activity and a predictor of progressive joint destruction in the wrists of patients with rheumatoid arthritis. Arthritis Rheum 1999; 42: 918-29.
47. Savnik A, Malmskov H, Thomsen HS, Graff LB, Nielsen H, Danneskiold-Samsoe B, et al. MRI of the wrist and finger joints in inflammatory joint diseases at 1-year interval: MRI features to predict bone erosions. Eur Radiol 2002; 12: 1203-10.
48. Stewart NR, Crabbe JP, McQueen FM,. Magnetic resonance imaging of the wrist in rheumatoid arthritis: demonstration of progression between 1 and 6 years. Skeletal Radiol 2004; 33: 704-11.
49. Stewart NR, McQueen FM, Crabbe JP,. Magnetic resonance imaging of the wrist in early rheumatoid arthritis: a pictorial essay. Australas Radiol 2001; 45: 268-73.
50. Tanaka N, Sakahashi H, Ishii S, Sato E, Hirose K, Ishima T,. Synovial membrane enhancement and bone erosion by magnetic resonance imaging for prediction of radiologic progression in patients with early rheumatoid arthritis. Rheumatol Int 2005; 25: 103-7.
51. McQueen FM, Benton N, Crabbe J, Robinson E, Yeoman S, McLean L, et al. What is the fate of erosions in early rheumatoid arthritis? Tracking individual lesions using x rays and magnetic resonance imaging over the first two years of disease. Ann Rheum Dis 2001; 60: 859-68.
52. Lindegaard H, Vallo J, Horslev-Petersen K, Junker P, Ostergaard M,. Low field dedicated magnetic resonance imaging in untreated rheumatoid arthritis of recent onset. Ann Rheum Dis 2001; 60: 770-6.
53. Lindegaard HM, Vallo J, Horslev-Petersen K, Junker P, Ostergaard M,. Low-cost, low-field dedicated extremity magnetic resonance imaging in early rheumatoid arthritis: a 1-year follow-up study. Ann Rheum Dis 2006; 65: 1208-12.
54. McQueen FM, Benton N, Perry D, Crabbe J, Robinson E, Yeoman S, et al. Bone edema scored on magnetic resonance imaging scans of the dominant carpus at presentation predicts radiographic joint damage of the hands and feet six years later in patients with rheumatoid arthritis. Arthritis Rheum 2003; 48: 1814-27.
55. Haavardsholm EA, Boyesen P, Ostergaard M, Schildvold A, Kvien TK,. Magnetic resonance imaging findings in 84 patients with early rheumatoid arthritis: bone marrow oedema predicts erosive progression. Ann Rheum Dis 2008; 67: 794-800.
56. Boyesen P, Haavardsholm EA, van der Heijde D, Ostergaard M, Hammer HB, Sesseng S, et al. Prediction of MRI erosive progression: a comparison of modern imaging modalities in early rheumatoid arthritis patients. Ann Rheum Dis 2011; 70: 176-9.
57. Katayama K, Okubo T, Sato T, Fukai R, Miyoshi N, Matsuno T,. Bone marrow oedema is more associated with rapid radiographic progression than synovitis or bone erosion by using low field MRI in bio-naive rheumatoid arthritis patients treated with adalimumab and methotrexate combination therapy. Ann Rheum Dis 2012; 71 Suppl 3: 504.
58. Tamai M, Nakashima Y, Suzuki T, Okada A, Kita J, Horai Y, et al. The presence of magnetic resonance imaging-proven osteitis at entry predicts the development of rapid radiographic progression in patients with early rheumatoid arthritis. Ann Rheum Dis 2012; 71 Suppl 3: 338.
59. Hetland ML, Ejbjerg B, Horslev-Petersen K, Jacobsen S, Vestergaard A, Jurik AG, et al, and the CIMESTRA Study Group. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis: results from a 2-year randomised controlled trial (CIMESTRA). Ann Rheum Dis 2009; 68: 384-90.
60. Hetland ML, Stengaard-Pedersen K, Junker P, Ostergaard M, Ejbjerg BJ, Jacobsen S, et al, the CIMESTRA Study Group. Radiographic progression and remission rates in early rheumatoid arthritis-MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial. Ann Rheum Dis 2010; 69: 1789-95.
61. Baker J, Ostergaard M, Emery P, Hsia EC, Lu JD, Baker D, et al. Early magnetic resonance imaging measures independently predict 1- and 2-year x-ray progression: results from a large clinical trial [abstract]. Arthritis Rheum 2012; 64 Suppl: S692-3.
62. Benton N, Stewart N, Crabbe J, Robinson E, Yeoman S, McQueen FM,. MRI of the wrist in early rheumatoid arthritis can be used to predict functional outcome at 6 years. Ann Rheum Dis 2004; 63: 555-61.
63. Ostergaard M, Emery P, Conaghan PG, Fleischmann R, Hsia EC, Xu W, et al. Significant improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone: a magnetic resonance imaging study of 318 methotrexate-naive rheumatoid arthritis patients. Arthritis Rheum 2011; 63: 3712-22.
64. Conaghan PG, Emery P, Ostergaard M, Keystone EC, Genovese MC, Hsia EC, et al. Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial. Ann Rheum Dis 2011; 70: 1968-74.
65. Moller Dohn U, Boonen A, Hetland ML, Hansen MS, Knudsen LS, Hansen A, et al. Erosive progression is minimal, but erosion healing rare, in patients with rheumatoid arthritis treated with adalimumab: a 1 year investigator-initiated follow-up study using high-resolution computed tomography as the primary outcome measure. Ann Rheum Dis 2009; 68: 1585-90.
66. Dohn UM, Ejbjerg B, Boonen A, Hetland ML, Hansen MS, Knudsen LS, et al. No overall progression and occasional repair of erosions despite persistent inflammation in adalimumab-treated rheumatoid arthritis patients: results from a longitudinal comparative MRI, ultrasonography, CT and radiography study. Ann Rheum Dis 2011; 70: 252-8.
67. Kosta P, Voulgari P, Zikou A, Tsampoulas K, Drosos A, Argyropoulou M,. Effect of very early treatment in rheumatoid arthritis on bone oedema and synovitis, using magnetic resonance imaging. Scand J Rheumatol 2012; 41: 339-44.
68. Ostergaard M, Duer A, Nielsen H, Johansen JS, Narvestad E, Ejbjerg BJ, et al. Magnetic resonance imaging for accelerated assessment of drug effect and prediction of subsequent radiographic progression in rheumatoid arthritis: a study of patients receiving combined anakinra and methotrexate treatment. Ann Rheum Dis 2005; 64: 1503-6.
69. Haavardsholm EA, Ostergaard M, Ejbjerg BJ, Kvan NP, Uhlig TA, Lilleas FG, et al. Reliability and sensitivity to change of the OMERACT rheumatoid arthritis magnetic resonance imaging score in a multireader, longitudinal setting. Arthritis Rheum 2005; 52: 3860-7.
70. Bennett CL, Qureshi ZP, Sartor AO, Norris LB, Murday A, Xirasagar S, et al. Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease. Clin Kidney J 2012; 5: 82-8.
71. Albrecht A, Finzel S, Englbrecht M, Rech J, Hueber A, Schlechtweg P, et al. The structural basis of MRI bone erosions: an assessment by microCT. Ann Rheum Dis 2013; 72: 1351-7.